Infantile seborrhoeic dermatitis / cradle cap

Definition & Classification

Infantile seborrhoeic dermatitis (ISD) is the early-life phenotype of seborrhoeic dermatitis, classically presenting as cradle cap — greasy yellow scale on the scalp of young infants — with or without involvement of other seborrhoeic and intertriginous sites.[3][5][6] It is related to adult seborrhoeic dermatitis but is typically more self-limited as infantile sebum production declines.[5][6]

Spectrum:

• Mild pityriasiform scalp scale
• Classic cradle cap
• Intertriginous/napkin seborrhoeic pattern with fold involvement [1]

Epidemiology

Onset is usually within the first 3 months of life; most infants improve by 6–12 months.[6][7][8] Global seborrhoeic dermatitis meta-analysis shows meaningful population prevalence across ages, with lower rates in neonates than older groups overall — ISD remains one of the common rashes of early infancy in clinical practice.[9] Infants are typically systemically well.

Pathophysiology

Infantile sebum production is influenced by maternal androgens and early postnatal endocrine milieu, creating a lipid-rich habitat for Malassezia yeasts.[5][10] Yeast lipase activity and host inflammatory responses to fungal products and free fatty acids generate erythema with greasy scale on scalp and flexures.[10] As sebaceous activity falls later in infancy, the ecological drive often wanes and disease remits.[6]

Clinical Presentation

• Scalp: thick, greasy, yellow, adherent scales; salmon-pink base; vertex and anterior scalp common.[6][7]
• Face: eyebrows, glabella, nasolabial folds, retroauricular creases.
• Body: neck folds, axillae, inguinal/napkin folds involved (contrast irritant nappy dermatitis).
• Itch minimal or absent — infant usually comfortable relative to AD.[6][8]
• Feeding, growth and behaviour typically normal.

Differential Diagnosis

Bedside Assessment & Investigations

Diagnosis is clinical in typical well infants.[3][6] Examine all seborrhoeic sites, growth chart, and infection history. Investigations are selective: swab if superinfection; broader work-up if red flags for immunodeficiency or LCH.[7][8]

Management — First Line

Practical ladder used internationally: [1]

1. Reassure — usually self-limited.[6]
2. Soften scale with emollient or mineral/vegetable oil; leave on, then gently comb; never force scrape.[6][7]
3. Mild shampoo regimens for scalp.
4. Maintain skin hygiene in folds; barrier care if napkin area involved.

Cochrane 2019 found limited high-quality evidence for specific active interventions in ISD — counselling and gentle care remain foundational; treat inflammation/yeast when clinically needed without overstating certainty.[1][2]

Management — Medicated Topicals

• Short course low-potency topical corticosteroid (e.g. hydrocortisone class teaching) for inflamed scalp/skin when scale care alone is insufficient.[3][4]
• Topical imidazole antifungals (e.g. clotrimazole/ketoconazole cream teaching) when yeast-driven or persistent intertriginous disease is suspected.[3][4]
• Avoid prolonged potent steroids on infant scalp/face — atrophy and HPA suppression risk.[3]
• Adult innovations (e.g. roflumilast foam) are not the standard cradle-cap pathway for young infants.

Complications & Pitfalls

• Secondary bacterial or candidal infection.
• Steroid misuse by caregivers.
• Misdiagnosis of AD leading to under-treatment of itch, or mislabel of LCH as stubborn cradle cap.
• Parental distress out of proportion to medical risk — address with clear prognosis. [1]

Special Populations & Red Flags

Immunodeficiency: severe, widespread, refractory seborrhoeic-like dermatitis with failure to thrive, diarrhoea or recurrent infections warrants immunology/paediatric work-up (exam classic includes entities such as leucocyte adhesion deficiency in broader differentials of severe infantile dermatitis).[5][8]
LCH: seborrhoeic-like eruption that is erosive, purpuric, or treatment-resistant with systemic features — biopsy pathway.
Overlap: some infants evolve toward atopic phenotypes; reassess if itch dominates.

Prognosis & Follow-Up

Most improve within the first year.[6] Infantile disease does not reliably predict adult seborrhoeic dermatitis. Re-review if not improving, if itch escalates (consider AD), or if red flags appear.

Evidence, Guidelines & Regional Notes

Exam anchors: Cochrane ISD review,[1] JAAD Cochrane summary,[2] AFP diagnosis/treatment overviews,[3][7] comprehensive treatment review,[4] classic JEADV SD review,[5] cradle cap clinical reviews,[6][8] global prevalence meta-analysis,[9] and Malassezia biology update.[10] ANZ/UK/India practice converges on gentle scale care first; medicated topicals second; systemic therapy almost never for uncomplicated cradle cap.

Exam Pearls

Red Flags

Exam application bank (NEET-PG / INICET)

One-line answer

Infantile seborrhoeic dermatitis (cradle cap) is a common early-life inflammatory dermatosis of sebum-rich sites with greasy yellow scale, minimal itch, and usual spontaneous improvement by 6–12 months. Exams test differentiation from infantile atopic and nappy dermatitis, Malassezia–sebum pathophysiology, emollient/scale-softening care, cautious low-potency steroid or topical imidazole use, Cochrane evidence limits, and red flags for immunodeficiency or Langerhans cell histiocytosis.

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Infantile seborrhoeic dermatitis / cradle cap.

Expanded exam teaching (depth pass)

Clinical reasoning

For Infantile seborrhoeic dermatitis / cradle cap, examiners test whether you can prioritise life threats, choose the right first test, and give specific therapy (agent, dose, route, timing). Generic phrases without numbers score poorly.

Mechanism → feature map

Build a short chain: cause → pathophysiologic intermediate → clinical feature → complication. Every major symptom in the classic vignette should sit on that chain.

Investigation strategy

• Bedside/first-line tests that change immediate management
• Confirmatory or staging tests
• What a normal result does not exclude
• When not to delay treatment for imaging (unstable patient)

Management ladder

1. Resuscitation / ABC / sepsis or haemorrhage bundle as relevant
2. Specific antidote / procedure / antimicrobial / reperfusion / surgery
3. Supportive care and monitoring targets
4. Definitive long-term therapy and secondary prevention
5. Disposition and safety-net advice

Special populations

Always prepare one line each for children, pregnancy, elderly, renal/hepatic impairment, and immunocompromised patients when the topic allows.

Pitfalls that fail candidates

• Treating the number not the patient
• Missing pregnancy status when relevant
• Imaging before stabilisation
• Wrong empiric cover or wrong antidote timing
• Incomplete counselling on recurrence, adherence, or red-flag return

Infantile seborrhoeic dermatitis (cradle cap) is a common early-life inflammatory dermatosis of sebum-rich sites with greasy yellow scale, minimal itch, and usual spontaneous improvement by 6–12 months. Exams test differentiation from infantile atopic and nappy dermatitis, Malassezia–sebum pathophysiology, emollient/scale-softening care, cautious low-potency steroid or topical imidazole use, Cochrane evidence limits, and red flags for immunodeficiency or Langerhans cell histiocytosis. [1]

Structured revision sheet

Must-know numbers and names

List every score, size threshold, dose, and time window from this topic on a blank page from memory, then check against the sections above.

Three classic MCQ angles

1. Most likely diagnosis given a vignette
2. Next best step in management
3. Most appropriate investigation

Three classic SAQ angles

1. Pathophysiology in five steps
2. Management algorithm with doses
3. Complications and prevention

Clinical station flow

Greet → focused history → targeted exam → investigations → explain diagnosis → emergency care → definitive plan → safety-net / follow-up → answer examiner questions on mechanism and pitfalls.

[1]

References

1. [1]Victoire A, Magin P, Coughlan J, et al. Interventions for infantile seborrhoeic dermatitis (including cradle cap) Cochrane Database Syst Rev, 2019.PMID 30828791
2. [2]Hassan S, Szeto MD, Sivesind TE, et al. From the Cochrane Library: Interventions for infantile seborrheic dermatitis (including cradle cap) J Am Acad Dermatol, 2022.PMID 34571061
3. [3]Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis Am Fam Physician, 2015.PMID 25822272
4. [4]Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review J Dermatolog Treat, 2019.PMID 29737895
5. [5]Gupta AK, Bluhm R. Seborrheic dermatitis J Eur Acad Dermatol Venereol, 2004.PMID 14678527
6. [6]Nobles T, Harberger S, Krishnamurthy K. Cradle Cap(Archived) 2026.PMID 30285358
7. [7]O'Connor NR, McLaughlin MR, Ham P. Newborn skin: Part I. Common rashes Am Fam Physician, 2008.PMID 18236822
8. [8]Chadha A, Jahnke M. Common Neonatal Rashes Pediatr Ann, 2019.PMID 30653638
9. [9]Polaskey MT, Chang CH, Daftary K, et al. The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis JAMA Dermatol, 2024.PMID 38958996
10. [10]Adalsteinsson JA, Kaushik S, Muzumdar S, et al. An update on the microbiology, immunology and genetics of seborrheic dermatitis Exp Dermatol, 2020.PMID 32125725